Phosphodiesterase Type 5 Inhibitors for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
|
|
- Meagan Osborne
- 5 years ago
- Views:
Transcription
1 Urol Sci 2010;21(1):2 7 CME Credits MINI REVIEW Phosphodiesterase Type 5 Inhibitors for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Shih-Tsung Huang* Division of Andrology and Female Urology, Department of Urology and Surgery, Chang Gung Memorial Hospital Linkou, Chang Gung University, College of Medicine, Taoyuan, Taiwan Erectile dysfunction (ED) and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are two common diseases among men aged over 50. Population or community-based epidemiologic studies have shown higher prevalence of male ED among men with LUTS associated with BPH. The exact mechanisms are unclear, but nitric oxide/cyclic guanosine monophosphate signal may be involved in the common pathway in the pathogenesis via smooth muscle relaxation control. Phosphodiesterase type 5 (PDE5) inhibitors have become the mainstay treatment of choice for male ED since the launch of sildenafil citrate in However, more evidence has shown that men receiving PDE5 inhibitors for their ED treatment have also benefited from improvement on their LUTS. Early randomized clinical studies has shown that daily dosing with PDE5 inhibitors (sildenafil, tadalafil and vardenafil) could improve the irritative or obstructive symptoms based on reduction in the International Prostate Symptom Score but had little effect on uroflow rate or post-voiding residuals. The combined use of PDE5 inhibitors and α-blockers has revealed more promising results on LUTS alleviation, but the safety profiles of this kind of combined use should be further evaluated and confirmed by greaterscale, randomized and comparative clinical studies. Accepted: May 8, 2009 KEY WORDS: erectile dysfunction; sildenafil; tadalafil; vardenafil *Corresponding author. Department of Urology, Chang Gung Memorial Hospital Linkou, 5, Fu-Hsing Street, Gueishan, Taoyuan 33333, Taiwan. huangst@cgmh.org.tw There are 2 CME questions based on this article 1. Introduction Lower urinary tract symptoms (LUTS) are defined by the International Continence Society as all urinary symptoms which occur during the phases of storage (increased daytime frequency, nocturia, urgency, and/or urinary incontinence), voiding (terminal dribble, hesitancy, intermittency, straining, and/or splitting/spraying/slow stream), and post-micturition (incomplete emptying or postmicturition dribble). 1 A population-based epidemiologic study using the 2002 International Continence Society definition showed that the prevalence of storage LUTS (men, 51.3%; women, 59.2%) was greater than that of voiding (men, 25.7%; women, 19.5%) and post-micturition (men, 16.9%; women, 14.2%) symptoms combined. 2 LUTS in men may be related to bladder dysfunction or bladder outlet obstruction, which is often associated with benign prostatic hyperplasia (BPH). Although α 1 adrenergic receptor antagonists (α-blockers) and 5α-reductase inhibitors are helpful in treating LUTS associated with BPH (LUTS/BPH), some storage symptoms such as nocturia or urgency may be refractory to standard treatment. The benefit of antimuscarinics in alleviating these symptoms should be weighed against the risks of urinary retention or treatment-related side effects such as dry mouth and constipation Taiwan Urological Association. Published by Elsevier Taiwan LLC.
2 Phosphodiesterase inhibitors and LUTS Since the launch of sildenafil citrate in 1998, phosphodiesterase type 5 (PDE5) inhibitors are extensively used as the first-line drug of choice for treating male erectile dysfunction (ED). With increasing evidence to support the close relationship between LUTS/BPH and ED, PDE5 inhibitors were used to treat LUTS in some preliminary studies with favorable outcomes. This mini review focuses on the rationale for using PDE5 inhibitors for LUTS/BPH treatment, updates clinical results regarding all three PDE5 inhibitors for LUTS/BPH treatment, and reviews the safety profiles of their concomitant use with α-blockers based on a literature review. 2. ED and LUTS Associated With BPH 2.1. Close Links Between ED and LUTS/ BPH Epidemiologic Evidence Since the 1990s, several population- or community-based epidemiologic studies have shown that urinary symptoms might have direct impact on sexual dysfunction and satisfaction with one s sexual life. 3 6 In a large, communitybased study conducted in France involving 2011 men aged years, Macfarlane et al. 3 found that the severity of overall urinary symptoms was inversely related to satisfaction with one s sexual life, and the association persisted after adjusting for various factors of age and the frequency of sexual relations. 3 In a multinational study involving 423 men aged 40 years in a community population in the UK and 1271 people visiting a urology clinic aged 45 years in 12 countries, the authors found that patients with LUTS, especially those with storage symptoms associated with incontinence had a higher odds ratio for sexual dysfunction. 4 Braun et al. 5 found that the prevalence of LUTS in men suffering from ED was about 72.2% (n = 621) versus 37.7% (n = 1367) in men with normal erections. The occurrence of LUTS can be considered an age-independent risk factor for the development of ED with an odds ratio of 2.11 (p < 0.001). 5 In a multinational survey involving 12,825 men aged years, sexual disorders and their impact on quality of life were strongly related to both age and the severity of LUTS. The relationship between sexual disorders and LUTS was independent of comorbidities including diabetes, hypertension, cardiac disease, and hypercholesterolemia. 6 Recently, a population-based, cross-sectional internet survey enrolling 30,000 men and women aged > 40 years was conducted in the US (n = 20,000), the UK (n = 7500), and Sweden (n = 2500). Among 11,834 men with a mean age of 56.1 years, 71% reported being currently sexually active, and 26% of these sexually active men had mild to severe ED, 7% had ejaculation disorders, and 16% had premature ejaculation. ED was associated with an older age, hypertension, diabetes, depression, and LUTS including urgency with fear of leaking, a weak stream, a split stream, leaking during sexual activity, and dysuria. 7 A population-based data survey study conducted in the UK also showed that men with a diagnosis of LUTS had a significantly increased prevalence of all kinds of sexual dysfunction compared with men without LUTS, and a diagnosis of LUTS even preceded the diagnosis of sexual dysfunction in a majority of men Nitric Oxide/Cyclic Guanosine Monophosphate A Common Mechanism of ED and LUTS Although there are strong links between ED and LUTS based on epidemiologic evidence, the exact mechanisms are still unclear. Smooth muscle tone and function may play important roles in both erection function and urinary bladder physiology. Since the discovery of nitric oxide (NO) as the major nonadrenergic noncholinergic neurotransmitter in penile erection, the NO/cyclic guanosine monophosphate (cgmp) pathway with an inhibitory effect on smooth muscles and nerves of the lower urinary tract (LUT) was postulated as one of the major component in urination control NO-mediated smooth muscle relaxation was also demonstrated in the human bladder neck, trigone, sphincter, and prostate. 12,13 LUT smooth muscles can be relaxed by drugs that increase the intracellular concentrations of cyclic adenosine monophosphate (camp) and cgmp. In LUT smooth muscles, increases in camp seem to play a major role in bladder relaxation, whereas cgmp is more important for urethral relaxation. 14,15 Furthermore, NO released from the uro thelium was implicated in suppressing excitatory signals from adjacent afferent nerves. On the other hand, overexpression of NO synthase and increased release of NO from the urothelium were found in an animal model with interstitial cystitis, which might be attributed to bladder overactivity induced by inflammation. 16,17 Interestingly, systemic administration of 20 mg of isosorbide dinitrate as an NO donor sublingually in 11 healthy volunteers in a pressure flow study produced a decreased in the average detrusor pressure during micturition of 57 to 52 cmh 2 O, while the average uroflow rate increased from 16.7 to 20.2 ml/s. The authors concluded that systemic NO administration can lower the functional bladder outlet resistance in men, and the NO/cGMP pathway might be a promising target for medical treatment of LUTS. 18 In addition to the NO/ cgmp pathway, there are other possible mechanisms, including pelvic atherosclerosis/ischemia, the autonomic hyperactivity/metabolic syndrome hypo thesis and the Rho-kinase activation/endothelin pathway, which might explain the relationship between ED and LUTS/BPH. 19,20 3. Distribution of Phosphodiesterases (PDEs) in the LUT PDEs, a heterogeneous group of hydrolytic enzymes, inactivate the camp and cgmp intracellular signals and are Vol. 21, 2 7, March
3 S.T. Huang involved in smooth muscle tone regulation. In total, 11 distinct families with 21 human genes were identified based on their amino acid sequences, cyclic nucleotide substrates, and catalytic considerations. 21 PDE1, -2, -3, -4, -5 and -9 were identified in the human urinary bladder. 22 Werkstrom et al. 23 characterized the distributions of PDE5 and cgmp in the human urethra, and the smooth muscle relaxant effect was associated with increased levels of cgmp. Almost all of the PDEs found in the human prostate are highly expressed as the PDE9A and PDE11A isoforms. 14 Secondary messengers including cgmp and camp were found to be involved in the control of the normal function of the prostate. Uckert et al. 24 further demonstrated by an immunohistologic method the presence of PDE4 in the fibromuscular stroma of the prostate as well as in glandular structures of the transition zone. In contrast to the distribution of PDE4, the presence of PDE5 and PDE11 was mainly observed in glandular and stromal regions. 24 The presence and functional relevance of PDE isoenzymes 1, 4, and 5 in human prostatic tissue support the possible use of inhibitors of PDE1, -4, and -5 to treat urinary obstruction secondary to BPH. 11,25 27 An in vitro prostate tissue study also confirmed that PDE4 and -5 inhibitors can reverse the tension induced by norepinephrine, and the most prominent enhancement in tissue cgmp levels could be significantly elevated by tadalafil, vardenafil and sildenafil to different degrees (28-fold, 12-fold and threefold, respectively). 28 Treatment with selective PDE4 inhibitors showed their ability to reduce bladder overactivity and to suppress experimental bladder inflammation in animal studies. 29,30 Recently, Bittencourt et al. 13 further confirmed that sildenafil was effective in inducing bladder neck smooth muscle relaxation in vitro, and this effect could be abolished by Nω-nitro-L-arginine methyl ester (L-NAME), which further indicated the dependence of the NO/cGMP pathway in the bladder neck. 4. Clinical Results of PDE5 Inhibitors for LUTS Treatment Different kinds of PDE1, -4 and -5 inhibitors were used to verify their effectiveness in treating LUTS. In a pilot study using the PDE1 inhibitor, vinpocetine, 11 of 19 patients (57.9%) with urge incontinence and a low-compliance bladder and who were nonresponders to standard pharmacologic therapy showed improvements in clinical symptoms and/or urodynamic parameters. 31 With the extensive use of PDE5 inhibitors in the treatment of male ED since 1998, more clinical data show that PDE5 inhibitors appear to improve erectile function as well as urinary symptom scores. In an observational, nonrandomized study conducted in 2002 which enrolled 112 male patients for ED treatment, concomitant International Prostate Symptom Score (IPSS) evaluations after 1 3 months of sildenafil treatment showed a trend towards improvements in the IPSS. A lower IPSS at the baseline appeared to predict a better response to sildenafil. 32 In another open-label study, 48 men (with a mean age of 62 years) with ED and an IPSS of 10 were enrolled to receive on-demand sildenafil citrate treatment for 3 months. About 60% of these men showed an improvement in their IPSS with a mean 4.6-point reduction, but only 35% of them had more than a 4-point improvement. 33 In a double-blind, placebo-controlled trial in 25 patients with spinal cord injury who had ED and micturition disorders, a urodynamic study done 1 3 hours after the oral administration of 20 mg of vardenafil showed an increased bladder capacity (253 vs. 296 ml; p = 0.004) and reduced maximal detrusor pressure (57 vs. 52 cmh 2 O; p = 0.039). 34 Furthermore significant improvements in LUTS were demonstrated in several large, multicenter, randomized, placebo-controlled trials (Table 1) However, most of those studies showed that PDE5 inhibitors could only improve the irritative or obstructive symptoms based on IPSS reduction but had little effect on uroflowmetric parameters or the post-voiding residual volume. The combined use of PDE5 inhibitors and α-blockers seems to have more-promising results than monotherapy alone in terms of IPSS reduction or mean maximal uroflow rate (Qmax) improvement. One possible explanation for this poor uroflow rate response with PDE5 inhibitors alone may be the predominant effects of non-voiding contractions by these PDE5 inhibitors. 27 Aging, the static component of the prostate in bladder outlet obstruction, sympathetic tone overactivity, and androgen-dependent PDE5 inhibitor activity were cited as possible factors influencing the responses. 11, Safety Concerns About Combined Therapy With a-blockers The concurrent reduction of the sympathetic tone within the LUT by α-blockers and inhibition of prostate growth by 5α-reductase inhibitors are still the main strategy in medical management of LUTS/BPH. Although early clinical results showed the potential of using PDE5 inhibitors to improve LUTS/BPH, the safety profiles of the combined use of α-blockers and PDE5 inhibitors in LUTS/BPH treatment are not well established. According to the label information, none of the three PDE5 inhibitors should be taken with α-blockers other than tamsulosin because of the risk of adverse vasodilatory events. 46 However, a randomized placebo-controlled study confirmed the safety and efficacy of the combined use of 4 mg of doxazosin daily and 100 mg of sildenafil on-demand for treating non-organic ED men who were sildenafil nonresponders. 47 A similar hemodynamic evaluation was conducted in 16 men with BPH, and the blood pressure was measured in both the supine and passive orthostatic positions after 0.4 mg of tamsulosin daily for 4 Vol. 21, 2 7, March 2010
4 Phosphodiesterase inhibitors and LUTS Table 1 Summary of recent randomized clinical studies for phosphodiesterase type 5 inhibitors in treating lower urinary tract symptoms associated with benign prostatic hyperplasia Author (publication year) Arm/drug (no. of patients) Mean IPSS Qmax (ml/s) Baseline Week 12 Change Baseline Week 12 Change McVary et al. 35 (2007) Placebo (180) Sildenafil 50 or 100 mg qd (189) 6.32* McVary et al. 36 (2007) Placebo (143) Tadalafil 5 or 20 mg qd (138) * Stief et al. 38 (2008) Placebo (113) Vardenafil 10 mg bid (108) * Roehrborn et al. 39 (2008) Placebo (212) Tadalafil 2.5 mg qd (209) 3.88* mg qd (212) 4.87* mg qd (216) 5.17* mg qd (209) 5.21* Kaplan et al. 37 (2007) Alfuzosin 10 mg qd (20) * * Sildenafil 25 mg qd (21) * Combination (21) * * Bechara et al. 40 (2008) Tamsulosin 0.4 mg qd * placebo (30) Tamsulosin 0.4 mg qd + tadalafil * mg qd (30) Liguori et al. 41 (2009) Alfuzosin 10 mg qd (18) * * Tadalafil 20 mg qod (19) * Combination (21) * * *p < IPSS = International Prostate Symptom Score; Qmax = mean maximal uroflow rate; = not available; qd = everyday; bid = twice a day; qod = every other day. 14 days and a single dose of 100 mg of sildenafil or a placebo. The authors confirmed that the combined use of tamsulosin and sildenafil decreased the systemic blood pressure and vascular resistance index in the supine position. 48 The safety of the combined use of alfuzosin and tadalafil was evaluated in a randomized, double-blind, placebo-controlled, crossover study. Eighteen healthy volunteers who received 10 mg of alfuzosin daily for 7 days were randomized to receive on-demand 20 mg of tadalafil or a placebo on the 7th day. Only a 4-mmHg difference in the standing systolic blood pressure was noted between the tadalafil and placebo groups. 49 Recently, in a randomized, double-blind, placebo-controlled, crossover study, 38 patients with BPH and ED, who were treated with 4 mg of doxazosin (67.6%) daily or 8 mg (32.4%) on a regular basis, were enrolled. The standing and supine blood pressures were measured 1 hour before and 6 hours after the administration of 10 mg of vardenafil. A maximal decrease in systolic pressure of 6.18 mmhg in the standing position was found with the combined use of doxazosin and vardenafil. The authors concluded that a single dose of 10 mg of vardenafil had no hypotensive effects on patients receiving regular doxazosin treatment. 50 Although there are usually small additive re ductions in blood pressure without significant adverse events, some patients may still develop orthostatic hypotension when these PDE5 inhibitors are used in patients receiving regular α-blocker treatment. Precautions are necessary for all three PDE5 inhibitors regarding this potential interaction Conclusion Men with a diagnosis of LUTS have a significantly increased prevalence of all kinds of sexual dysfunction compared with those men without LUTS. The NO/cGMP pathway, which has an inhibitory effect on smooth muscles and nerves of the LUT, is postulated to be one of the major components in their regulation. Early randomized clinical studies showed that daily dosing with PDE5 inhibitors could improve the irritative or obstructive symptoms based on IPSS reduction but had little effect on uroflowmetric parameters or post-voiding residuals. The combined use of PDE5 inhibitors and α-blockers showed more-promising results, but the safety concerns of this combined use should be further evaluated and confirmed by additional randomized and comparative clinical studies. Vol. 21, 2 7, March
5 S.T. Huang References 1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21: Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50: Macfarlane GJ, Botto H, Sagnier PP, Teillac P, Richard F, Boyle P. The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol 1996;49: Frankel SJ, Donovan JL, Peters TI, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998;51: Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical Aging Male symptoms? Results of the Cologne Male Survey. Eur Urol 2003;44: Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44: Wein AJ, Coyne KS, Tubaro A, Sexton CC, Kopp ZS, Aiyer LP. The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int 2009;103(Suppl 3): Morant S, Bloomfield G, Vats V, Chapple C. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med 2009;6: Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990;170: Hedlund P. Nitric oxide/cgmp-mediated effects in the outflow region of the lower urinary tract is there a basis for pharmacological targeting of cgmp? World J Urol 2005;23: Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 2007;26: Ho MH, Bhatia NN, Khorram O. Physiologic role of nitric oxide and nitric oxide synthase in female lower urinary tract. Curr Opin Obstet Gynecol 2004;16: Bittencourt JA, Tano T, Gajar SA, et al. Relaxant effects of sildenafil on the human isolated bladder neck. Urology 2009;73: Wheeler MA, Ayyagari RR, Wheeler GL, Weiss RM. Regulation of cyclic nucleotides in the urinary tract. J Smooth Muscle Res 2005; 41: Morita T, Tsujii T, Dokita S. Regional difference in functional roles of camp and cgmp in lower urinary tract smooth muscle contractility. Urol Int 1992;49: Birder LA, Apodaca G, de Groat WC, Kanai AJ. Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 1998;275:F de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006;147(Suppl 2):S Muntener M, Schurch B, Wefer B, et al. Systemic nitric oxide augmentation leads to a rapid decrease of the bladder outlet resistance in healthy men. Eur Urol 2006;50: McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006;97(Suppl 2):23 8; Gur S, Kadowitz PJ, Hellstrom WJG. Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction: implications for sexual dysfunction. Drugs 2008;68: Maurice DH, Palmer D, Tilley DG, et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003;64: Truss MC, Uckert S, Stief CG, Kuczyk M, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle, I: identification and characterization. Urol Res 1996;24: Werkstrom V, Svensson A, Andersson KE, et al. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 2006;98: Uckert S, Oelke M, Stief CG, et al. Immunohistochemical distribution of camp- and cgmp-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006;49: Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle, II: effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 1996;24: Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001;166: Tinel H, Stelte-Ludwig B, Hutter J, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006;98: Uckert S, Sormes M, Kedia G, et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008;71: Kitta T, Tanaka H, Mitsui T, et al. Type 4 phosphodiesterase inhibitor suppresses experimental bladder inflammation. BJU Int 2008;102: Kaiho Y, Nishiguchi J, Kwon DD, et al. The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int 2008;101: Truss MC, Stief CG, Uckert S, et al. Initial clinical experience with the selective phosphodiesterase-i isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol 2000;18: Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: Mulhall JP, Guhring P, Parker M, et al. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3: Gacci M, Del Popolo G, Macchiarella A, et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007;178: McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007;177: McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177: Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51: Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008;53: Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180: Bechara A, Romano S, Casabe A, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH: pilot study. J Sex Med 2008;5: Vol. 21, 2 7, March 2010
6 Phosphodiesterase inhibitors and LUTS 41. Liguori G, Trombetta C, De Giorgi G, et al. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009;6: Reitz A, Muntener M, Haferkamp A, et al. Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/ cgmp pathway? BJU Int 2005;96: Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148: Pimentel H, Wald M, Niederberger C. Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms. Int J Impot Res 2008;20: Giuliano F. Phosphodiesterase type 5 inhibitors improve male lower urinary tract symptoms. Eur Urol 2008;53: Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004;64: De Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002;14: Nieminen T, Tammela TL, Koobi T, et al. The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol 2006;176: Giuliano F, Kaplan SA, Cabanis MJ, Astruc B. Hemodynamic interaction study between the alpha 1 -blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 2006;67: Ng CF, Wong A, Cheng CW, et al. Effect of vardenafil on blood pressure profile of patients with erectile dysfunction concomitantly treated with doxazosin gastrointestinal therapeutic system for benign prostatic hyperplasia. J Urol 2008;180: Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005;96(Suppl):42M 46M. Vol. 21, 2 7, March
EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationMMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS
Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47 Original Research Article Tadalafil therapy
More informationfor ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology
Tadalafil 5 mg once daily for ED and LUTS/BPH Pierre Sarkis, M.D. Assistant Professor Fellow of the European Board of Urology Why this conference? Not promotional but educational The pharmacist regularly
More informationEffects of Isosorbide Dinitrate on the Urinary Flow Rate in Patients With Benign Prostatic Hyperplasia
Miscellaneous Effects of Isosorbide Dinitrate on the Urinary Flow Rate in Patients With Benign Prostatic Hyperplasia Ali Roshani, 1 Iraj Khosropanah, 1 Mohammad Salehi, 1 Alireza Noshad Kamran 2 Keywords:
More informationImpact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
www.kjurology.org DOI:10.4111/kju.2011.52.1.49 Sexual Dysfunction Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile
More informationPhosphodiesterase Type 5 Inhibitors in the Management of Non-neurogenic Male Lower Urinary Tract Symptoms: Critical Analysis of Current Evidence
EUROPEAN UROLOGY 60 (2011) 527 535 available at www.sciencedirect.com journal homepage: www.europeanurology.com Collaborative Review Benign Prostatic Hyperplasia Phosphodiesterase Type 5 Inhibitors in
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationEvaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication
ORIGINal article Vol. 38 (1): 33-39, January - February, 2012 Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication
More informationEUROPEAN UROLOGY 61 (2012)
EUROPEAN UROLOGY 61 (12) 994 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Benign Prostatic Hyperplasia A Systematic Review and Meta-analysis on the Use of Phosphodiesterase
More informationREVIEW Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link
(2008) 20, S27 S32 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying
More informationeuropean urology 53 (2008)
european urology 53 (2008) 1236 1244 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Enlargement A Randomised, Placebo-Controlled Study to Assess the Efficacy
More informationMANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH
MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size
More information김준철 가톨릭대학교의과대학비뇨기과학교실
비뇨기계자율신경병증의치료 김준철 가톨릭대학교의과대학비뇨기과학교실 Introduction Urologic complications have increasingly become a concern in those affected by DM Genitourinary problems are included among these complications, related
More informationINTRODUCTION MISCELLANEOUS
MISCELLANEOUS Comparing Monotherapy with Tadalafil or Tamsulosin and Their Combination Therapy in Men with Benign Prostatic Hyperplasia: A Randomized Clinical Trial Hossein Karami*, Amin Hassanzadeh-Hadad,
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationAssociation of BPH with OAB: The Plumbing or the Pump?
Association of BPH with OAB: The Plumbing or the Pump? Ryan P. Terlecki, MD FACS Associate Professor of Urology Director, Men s Health Clinic Director, GURS Fellowship in Reconstructive Urology, Prosthetic
More informationORIGINAL ARTICLE. Keywords: doxazosin GITS; erectile dysfunction; IPSS; lower urinary tract symptoms; quality of life; sildenafil
(2011) 13, 630 635 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE An open, comparative, multicentre clinical study of combined oral therapy with sildenafil
More informationEffect of acute administration of sildenafil to rats with detrusor overactivity induced by chronic deficiency of nitric oxide
ORIGINAL Article Vol. 39 (2): 268-275, March - April, 2013 doi: 10.1590/S1677-5538.IBJU.2013.02.16 Effect of acute administration of sildenafil to rats with detrusor overactivity induced by chronic deficiency
More informationORIGINAL ARTICLE. Division of Urology and 2 Department of Pharmacology, Universidade Federal do Ceara, CE, Brazil INTRODUCTION
ORIGINAL ARTICLE Vol. 40 (4): 546-552, July. August, 2014 doi: 10.1590/S1677-5538.IBJU.2014.04.15 Effects of chronic administration of tamsulosin and tadalafil, alone or in combination, in rats with bladder
More informationTadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis
LUTS (2018) 10, 84 92 ORIGINAL ARTICLE Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis Yilin WANG, 1 Yiping BAO, 2, Jie LIU,
More informationRESEARCH PAPER Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth musclebph_
British Journal of Pharmacology (21), 16, 1135 1143 21 The Authors Journal compilation 21 The British Pharmacological Society All rights reserved 7-1188/1 www.brjpharmacol.org RESEARCH PAPER Signalling
More informationNOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate
NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationDiagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center
Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition
More informationL ower urinary tract symptoms (LUTS) are a major health problem and are prevalent in men aged.45 years1 3.
OPEN SUBJECT AREAS: UROGENITAL DISEASES DRUG DEVELOPMENT Received 23 October 2013 Accepted 15 January 2014 Published 4 February 2014 Correspondence and requests for materials should be addressed to P.H.
More informationTzu Chi Medical Journal
Tzu Chi Medical Journal 25 (2013) 98e102 Contents lists available at SciVerse ScienceDirect Tzu Chi Medical Journal journal homepage: www.tzuchimedjnl.com Original Article First-line antimuscarinic monotherapy
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationLower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist
Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,
More informationEvaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Evaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients N. Narayanamoorthy,
More informationBasic and Translational Research. Jung Yoon Kang, Eun Kyung Kim 1, Kwang Myung Kim 2.
www.kjurology.org http://dx.doi.org/0.4/kju.203.54.5.339 Basic and Translational Research Effects of Mirodenafil, a Phosphodiesterase-5 Inhibitor, on Female Rat Bladder in a Partial Bladder Outlet Obstruction
More informationSexual dysfunction in male LUTS. M. Gacci Department of Urology, University of Florence
Sexual dysfunction in male LUTS M. Gacci Department of Urology, University of Florence Roma, 25-26 June, 2015 Cross-sectional population-based study of 4800 men (40 79 yr of age) UK, Netherlands, France,
More informationREVIEW The role of combination medical therapy in benign prostatic hyperplasia
(2008) 20, S33 S43 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW The role of combination medical therapy in benign prostatic hyperplasia Department of
More informationEjaculation. Emission. Ejection. Orgasm
Ejaculation Emission Ejection Orgasm Ejaculation sc T10-L2 S2-4 Emission: vas deferens, prostate, bladder neck Post. Urethra distention Ejection: Pelvic Floor / bulbocavernous muscle contraction Orgasm:
More informationThe Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence
european urology supplements 5 (2006) 849 853 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Evidence for Antimuscarinic Agents in Female Mixed Urinary Incontinence Stefano
More informationTADALAFIL THERAPY IN PATIENTS WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: RANDOMIZED, CONTROLLED TRIAL
AL-AZHAR ASSIUT MEDCAIL JOURNAL TADALAFIL THERAPY IN PATIENTS WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME: RANDOMIZED, CONTROLLED TRIAL Department of Urology, Al-Azhar University, Cairo, Egypt.
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More informationVOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS
VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS DR. FRANCIS LEE Voiding dysfunction Storage Emptying Common voiding dysfunction in elderly male Emptying BPH Storage Incontinence Overactive bladder Post-prostatectomy
More informationWhat is on the Horizon in Drug Therapy for OAB?
What is on the Horizon in Drug Therapy for OAB? K-E Andersson, MD, PhD Wake Forest Institute for Regenerative Medicine Wake Forest University School of Medicine Winston Salem, North Carolina Disclosures
More informationNational Institute for Health and Care Excellence. Lower Urinary Tract Symptoms Update Addendum Consultation Table 3 rd February 5 pm 3 rd March 2015
British Association of Urological Surgeons British Association of Urological Surgeons National Institute for Health and Care Excellence Lower Urinary Tract Symptoms Update Addendum Consultation Table 3
More informationOffice based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2
Office based non-oncology urology trials Richard W. Casey, MD, 1 Jack Barkin, MD 2 1 The Male Health Centre, Oakville, Ontario, Canada 2 Humber River Regional Hospital, University of Toronto, Toronto,
More informationManagement of male LUTS in general practice
17 Management of male LUTS in general practice MARK J. SPEAKMAN AND FAITH MCMEEKIN The initial management of lower urinary tract symptoms in men is usually carried out in primary care. The authors explain
More informationDIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH
More informationCombination Drug Therapy for Benign Prostatic Hyperplasia (BPH)
The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box
More informationLower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital
Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of
More informationORIGINAL ARTICLE. WJ Bang 1,CYOh 1,CYoo 1, JS Cho 1, DY Yang 1,DHLee 2, SH Lee 2 and BH Chung 2
International Journal of Impotence Research (2013) 25, 149 154 & 2013 Macmillan Publishers Limited All rights reserved 0955-9930/13 www.nature.com/ijir ORIGINAL ARTICLE Efficacy and safety of the simultaneous
More informationObjectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS
URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS Lisa S Pair, MSN, CRNP Division of Urogynecology and Pelvic Reconstructive Surgery Department of Obstetrics and Gynecology University of Alabama
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationOriginal Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:
Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras
More informationSexual Dysfunction in Aging Men With Lower Urinary Tract Symptoms
Sexual Dysfunction and Infertility Sexual Dysfunction in Aging Men With Lower Urinary Tract Symptoms Darab Mehraban, Gholam Hossein Naderi, Seyed Reza Yahyazadeh, Mahdi Amirchaghmaghi Introduction: Our
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationEUROPEAN UROLOGY 61 (2012)
EUROPEAN UROLOGY 61 (2012) 917 925 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Benign Prostatic Hyperplasia Editorial by Christopher R. Chapple on pp.
More informationα 1 adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 251-256, 2015 α 1 adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta analysis PENG ZHANG 1, WAN LI HU 1, BEI CHENG
More informationThe Enlarged Prostate Symptoms, Diagnosis and Treatment
The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda
More informationEfficacy and safety of tamsulosin OCAS
Original Article EFFICACY AND SAFETY OF TAMSULOSIN OCAS SPEAKMAN Efficacy and safety of tamsulosin OCAS MARK SPEAKMAN Taunton and Somerset Hospital, Taunton, UK The efficacy and safety of a new tablet
More informationUrinary Incontinence for the Primary Care Provider
Urinary Incontinence for the Primary Care Provider Diana J Scott FNP-BC https://youtu.be/gmzaue1ojn4 1 Assessment of Urinary Incontinence Urge Stress Mixed Other overflow, postural, continuous, insensible,
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationOveractive Bladder Syndrome
Overactive Bladder Syndrome behavioural modifications to pharmacological and surgical treatments Dr Jos Jayarajan Urologist Austin Health, Eastern Health Warringal Private, Northpark Private, Epworth Overactive
More informationImpact of smoking on Lower Urinary Tract Symptoms (LUTS) - Single tertiary centre experience
International Journal of Scientific and Research Publications, Volume 6, Issue 5, May 2016 119 Impact of smoking on Lower Urinary Tract Symptoms (LUTS) - Single tertiary centre experience AUB Pethiyagoda
More informationDiagnosis and Mangement of Nocturia in Adults
Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology
More informationVoiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.
Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.
More informationConclusions. Keywords
Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment Claus G. Roehrborn, Kathryn B.
More informationMale LUTS, OAB, Sex: natural history. JR Sathiya
Male LUTS, OAB, Sex: natural history JR Sathiya Definitions Newer concepts of LUTs Natural history of BPH Prevalence of LUTs Definition BPH- represents a histologic diagnosis that refers to the proliferation
More informationEfficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder
Urol Sci 21;21(1):38 43 ORIGINAL ARTICLE Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder Yih-Chou Chen, Chia-Yen Chen, Hann-Chorng
More informationNeurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.
Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.
More informationPrevalence, Severity, and Symptom Bother of Lower Urinary Tract Symptoms among Men in the EPIC Study: Impact of Overactive Bladder
EUROPEAN UROLOGY 56 (2009) 14 20 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Voiding Dysfunction Editorial by Christopher R. Chapple on pp. 21 23 of this
More informationSystematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms
EUROPEAN UROLOGY 64 (2013) 228 243 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Benign Prostatic Hyperplasia Editorial by Herbert
More information2/9/2008. Men Women. Prevalence of OAB. Men: 16.0% Women: 16.9% Prevalence (%) < Age (years)
Definition Botox for Overactive Bladder Donna Y. Deng Assistant Professor UCSF Department of Urology Urinary urgency With or without urge incontinence Usually with frequency & nocturia International Continence
More informationCialis. Cialis (tadalafil) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.02 Subject: Cialis Page: 1 of 5 Last Review Date: September 18, 2015 Cialis Description Cialis (tadalafil)
More informationOriginal Article - Sexual Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.9.608 Original Article - Sexual Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.9.608&domain=pdf&date_stamp=2014-09-16
More informationProfile of Silodosin. Francesco Montorsi * Article info. Abstract
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 491 495 available at www.sciencedirect.com journal homepage: www.europeanurology.com Profile of Silodosin Francesco Montorsi * Department of Urology, University Vita-Salute
More information3/20/10. Prevalence of OAB Men: 16.0% Women: 16.9% Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Dry. Population (millions) Wet
1 Prevalence of OAB Men: 16.0% Women: 16.9% Stewart WF, et al. World J Urol. 2003;20:327-336. Prevalence of OAB with incontinence (OAB wet) Men: 2.6% Women: 9.3% Stewart WF, et al. World J Urol. 2003;20:327-336.
More informationBotulinum Toxin: Applications in Urology
Botulinum Toxin: Applications in Urology Dr. Lee Jonat, PGY-4 Department of Urologic Sciences University of British Columbia Outline Mechanism of Action Technical Considerations Adverse Events Neurogenic
More informationAs man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5
BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG Beaconsfield Medical Practice, Brighton As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder
More informationPhosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2010.03828.x Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction Stefan Ückert 1,2 & Matthias Oelke 1
More informationOriginal Research Article
International Surgery Journal Singh SN et al. Int Surg J. 218 May;():1866-1872 http://www.ijsurgery.com pissn 2349-33 eissn 2349-292 Original Research Article DOI: http://dx.doi.org/1.1823/2349-292.isj218199
More informationMonth/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationLower UrinaryTract Symptoms (LUTS) and Sexual Function in Both Sexes
European Urology European Urology 46 (2004) 229 234 Lower UrinaryTract Symptoms (LUTS) and Sexual Function in Both Sexes Bjarne Lühr Hansen * Research Unit of General Practice, University of Southern Denmark,
More informationEfficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs
Sun et al. BMC Urology (2018) 18:30 https://doi.org/10.1186/s12894-018-0345-4 RESEARCH ARTICLE Open Access Efficacy and safety of PDE5-Is and α-1 blockers for treating lower ureteric stones or LUTS: a
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationThe patient, your co-pilot in assessing LUTS
The patient, your co-pilot in assessing LUTS Frank Van der Aa Leuven, Belgium This symposium is supported by Astellas Pharma Europe Ltd., including speaker honoraria and production of materials the slides
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationThe new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase 5 inhibitors
314 REVIEW PAPER FROM LAB TO CLINIC The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase 5 inhibitors Stanisław Wroński Department
More informationComparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder
European Urology European Urology 48 (2005) 110 115 Female UrologyöIncontinence Comparison of Symptom Severity and Treatment Response in Patients with Incontinent and Continent Overactive Bladder Martin
More informationObesity, Neural Influences, LUTS/BPH and PDE5 Inhibitors
Obesity, Neural Influences, LUTS/BPH and PDE5 Inhibitors Kevin T. McVary, MD-FACS Professor of Urology Feinberg School of Medicine Northwestern University Chicago, Illinois Obesity Trends* Among U.S. Adults
More informationThe impact of overactive bladder on quality of life in south of China
The impact of overactive bladder on quality of life in south of China Dong Chen, Yining Li * Department of Urology, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China. * Corresponding
More informationVoiding Dysfunction. Jae Hyun Bae, Sun Ouck Kim 1, Eun Sang Yoo 2, Kyung Hyun Moon 3, Yoon Soo Kyung 4, Hyung Jee Kim 4
www.kjurology.org DOI:10.4111/kju.2011.52.4.274 Voiding Dysfunction Efficacy and Safety of Low-Dose Propiverine in Patients with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia with Storage Symptoms:
More informationEffect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic Study
www.kjurology.org http://dx.doi.org/10.4111/kju.2013.54.12.840 Voiding Dysfunction/Female Urology Effect of Transurethral Resection of the Prostate Based on the Degree of Obstruction Seen in Urodynamic
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationTadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia
Central European Journal of Urology 167 REVIEW paper FUNCTIONAL UROLOGY Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia Alexander
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationRole of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia
[Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.
More informationSeasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
pissn: 2287-4208 / eissn: 2287-4690 World J Mens Health 2015 August 33(2): 81-87 http://dx.doi.org/10.5534/wjmh.2015.33.2.81 Original Article Seasonal Variation of Urinary Symptoms in Korean Men with Lower
More informationEXPERIMENTAL AND THERAPEUTIC MEDICINE 4: , 2012
1112 Usefulness of total bladder capacity and post void residual urine volume as a predictor of detrusor overactivity with impaired contractility in stroke patients SANG HYUB LEE, JOONG GEUN LEE, GYEONG
More informationSummary. Neuro-urodynamics. The bladder cycle. and voiding. 14/12/2015. Neural control of the LUT Initial assessment Urodynamics
Neuro-urodynamics Summary Neural control of the LUT Initial assessment Urodynamics Marcus Drake, Bristol Urological Institute SAFETY FIRST; renal failure, dysreflexia, latex allergy SYMPTOMS SECOND; storage,
More information